DE60118723D1 - Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten - Google Patents

Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten

Info

Publication number
DE60118723D1
DE60118723D1 DE60118723T DE60118723T DE60118723D1 DE 60118723 D1 DE60118723 D1 DE 60118723D1 DE 60118723 T DE60118723 T DE 60118723T DE 60118723 T DE60118723 T DE 60118723T DE 60118723 D1 DE60118723 D1 DE 60118723D1
Authority
DE
Germany
Prior art keywords
hydrogenotrophic
acetogenic
strains
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118723T
Other languages
English (en)
Other versions
DE60118723T3 (de
DE60118723T2 (de
Inventor
Michel Renaud
Annick Bernalier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Original Assignee
DIGESTAR SAINT-BEAUZIRE
DIGESTAR SAINT BEAUZIRE
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60118723(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DIGESTAR SAINT-BEAUZIRE, DIGESTAR SAINT BEAUZIRE, Institut National de la Recherche Agronomique INRA filed Critical DIGESTAR SAINT-BEAUZIRE
Application granted granted Critical
Publication of DE60118723D1 publication Critical patent/DE60118723D1/de
Publication of DE60118723T2 publication Critical patent/DE60118723T2/de
Publication of DE60118723T3 publication Critical patent/DE60118723T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
DE60118723T 2000-05-11 2001-05-11 Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten Expired - Lifetime DE60118723T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0006009A FR2808689B1 (fr) 2000-05-11 2000-05-11 Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
FR0006009 2000-05-11
PCT/FR2001/001426 WO2001085187A1 (fr) 2000-05-11 2001-05-11 Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs

Publications (3)

Publication Number Publication Date
DE60118723D1 true DE60118723D1 (de) 2006-05-24
DE60118723T2 DE60118723T2 (de) 2006-12-28
DE60118723T3 DE60118723T3 (de) 2010-09-30

Family

ID=8850107

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118723T Expired - Lifetime DE60118723T3 (de) 2000-05-11 2001-05-11 Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten

Country Status (13)

Country Link
US (2) US7749494B2 (de)
EP (1) EP1280541B2 (de)
JP (1) JP5183848B2 (de)
AT (1) ATE322902T1 (de)
AU (2) AU6040001A (de)
CA (1) CA2411563C (de)
CY (1) CY1107467T1 (de)
DE (1) DE60118723T3 (de)
DK (1) DK1280541T4 (de)
ES (1) ES2262650T5 (de)
FR (1) FR2808689B1 (de)
PT (1) PT1280541E (de)
WO (1) WO2001085187A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP4618970B2 (ja) * 2002-08-02 2011-01-26 マルホ株式会社 肛門圧低下外用剤
US7935334B2 (en) * 2005-07-07 2011-05-03 Imagilin Technologies, LLC Probiotics as alternative medicines against infectious diseases
US20060008511A1 (en) * 2004-07-08 2006-01-12 Jhy-Jhu Lin Probiotic products for pet applications
DE102006062250A1 (de) * 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
PL2072053T3 (pl) 2007-12-21 2013-02-28 Gervais Danone Sa Sposób zmniejszania obwodu brzucha przez podawanie bakterii bifidobacterium
EP2130543A1 (de) 2008-06-05 2009-12-09 Compagnie Gervais Danone Verfahren zur Verringerung von Borborygmus durch Verabreichung einer Bakterie der Gattung Bifidobacterium
SI3564357T1 (sl) 2010-02-01 2022-09-30 Rebiotix, Inc. Bakterioterapija Clostridium Difficile colitisa
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
HK1253538A1 (zh) * 2010-08-04 2019-06-21 Borody Thomas J 用於糞便菌群植入的組合物及其製備和使用方法
US9308226B2 (en) 2010-08-04 2016-04-12 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
KR101805873B1 (ko) * 2011-08-03 2018-01-10 한화케미칼 주식회사 단당류 인산 또는 그 유도체로 표면이 개질된 친수성 나노입자, 그의 콜로이드 용액 및 그 용도
EP4129312A1 (de) 2011-03-09 2023-02-08 Regents Of The University Of Minnesota Zusammensetzungen und verfahren zur transplantation von darmmikrobiota
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN104160014A (zh) 2011-12-01 2014-11-19 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
EP3461477B1 (de) 2012-03-29 2021-06-30 Therabiome, Llc Formulierungen zur gastrointestinalen oralen ortsspezifischen vakzination mit wirkung im ileum und wurmfortsatz
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
WO2014152338A1 (en) 2013-03-14 2014-09-25 Kabadi Mohan Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
AU2014275025B2 (en) 2013-06-05 2016-12-01 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2016102951A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Pirin polypeptide and immune modulation
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
MX2017010859A (es) 2015-02-27 2018-08-15 White Dog Labs Inc Metodo de fermentacion mixotrofica para poducir acetona, isopropanol, acido butirico y otros bioproductos, y mezclas de los mismos.
EP3294073B1 (de) 2015-05-11 2022-08-10 Mybiotics Pharma Ltd Systeme und verfahren zur züchtung eines biofilms von probiotischen bakterien auf festen partikeln zur kolonisation von bakterien im darm
CA2985827A1 (en) 2015-05-14 2016-11-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
NZ776366A (en) 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CN107921072A (zh) 2015-06-09 2018-04-17 雷柏奥提斯有限公司 微生物群恢复治疗（mrt）组合物和制造方法
TWI797058B (zh) 2015-06-15 2023-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MX2017016560A (es) * 2015-06-15 2018-02-21 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
MD3209310T2 (ro) 2015-11-20 2018-06-30 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
TW201733601A (zh) 2016-03-04 2017-10-01 ４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
KR102380134B1 (ko) 2016-05-25 2022-03-29 마이바이오틱스 파마 엘티디. 미생물총 치료를 위한 조성물 및 방법
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
GB201703552D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) * 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201703548D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) * 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP2020513018A (ja) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
SI3638271T1 (sl) 2017-06-14 2021-01-29 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
AU2018283994B2 (en) 2017-06-14 2021-03-18 4D Pharma Research Limited Compositions comprising bacterial strains
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
AU2019289190A1 (en) 2018-06-19 2021-01-07 4D Pharma Research Ltd Dosage form comprising a live biotherapeutic product
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN112566648A (zh) 2018-07-16 2021-03-26 4D制药研究有限公司 包含细菌菌株的组合物
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
EA202193075A1 (ru) 2019-05-10 2022-02-17 4Д Фарма Рисерч Лимитед Композиции, содержащие бактериальные штаммы
WO2021044376A1 (en) * 2019-09-05 2021-03-11 White Dog Labs, Inc. Mixotrophic probiotic compositions and uses thereof in the treatment of bloating
EP3839039A1 (de) 2019-12-16 2021-06-23 4D Pharma Research Limited Herstellung von bakterieller biomasse mit verbesserter lagerstabilität
TW202220639A (zh) 2020-08-06 2022-06-01 英商４Ｄ製藥有限公司 凍乾方法
WO2022112526A1 (en) 2020-11-26 2022-06-02 4D Pharma Leon, S.L.U. Process

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
AUPN698495A0 (en) * 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
ATE407700T1 (de) * 1996-03-20 2008-09-15 Univ New South Wales Veränderung der mikrobenflora im verdauungstrakt
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier
DE19826928A1 (de) † 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen
WO2000010581A1 (fr) * 1998-08-20 2000-03-02 Miyarisan Pharmaceutical Co., Ltd. Medicaments comprenant une combinaison d'une bacterie produisant de l'acide butyrique, et d'un constituant d'acide biliaire

Also Published As

Publication number Publication date
AU2001260400B2 (en) 2006-10-26
DK1280541T3 (da) 2006-07-17
EP1280541A1 (de) 2003-02-05
ATE322902T1 (de) 2006-04-15
AU6040001A (en) 2001-11-20
ES2262650T5 (es) 2010-06-28
DE60118723T3 (de) 2010-09-30
FR2808689B1 (fr) 2004-09-03
US20030147858A1 (en) 2003-08-07
CY1107467T1 (el) 2012-12-19
US7749494B2 (en) 2010-07-06
CA2411563A1 (fr) 2001-11-15
ES2262650T3 (es) 2006-12-01
CA2411563C (fr) 2012-12-11
JP2004501095A (ja) 2004-01-15
EP1280541B1 (de) 2006-04-12
EP1280541B2 (de) 2010-03-17
WO2001085187A1 (fr) 2001-11-15
JP5183848B2 (ja) 2013-04-17
US20100316617A1 (en) 2010-12-16
DE60118723T2 (de) 2006-12-28
FR2808689A1 (fr) 2001-11-16
PT1280541E (pt) 2006-06-30
DK1280541T4 (da) 2010-07-05

Similar Documents

Publication Publication Date Title
ATE322902T1 (de) Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
NO20061736L (no) Krystallform av epotilon B
ATE413386T1 (de) Ppar-gamma modulatoren
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
MX339420B (es) Compuestos para la modulacion de la actividad de ppar gamma.
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE69410254T2 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
HUP0402421A2 (hu) Mátrix-metalloproteinázokat gátló készítmény neopláziás betegségek kezelésére
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE405294T1 (de) Gezielt eingesetzte agenzien zur nervenregeneration
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DK1716128T3 (da) Substituerede 4,5,6,7-tetrahydrobenzothiazol-2-ylaminforbindelser
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
TR199801021T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome
ATE452189T1 (de) Anti-fragilis antikörper und dessen verwendungen
UA36490A (uk) Спосіб лікування гнійно-септичних захворювань м'яких тканин

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE,, FR

8366 Restricted maintained after opposition proceedings